Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by bball67on Sep 03, 2023 7:11pm
225 Views
Post# 35618378

Financing Was Obvious and Inevitable

Financing Was Obvious and Inevitable Wow, you guys have hyped yourselves into a conspiracy theory that Shareholders and the Boston Group was massively shorting the stock. That didn't happen. Acumen was to announce some preliminary clinical result on a Monday before market. It looks like Promis knew that and also issued a press release on the same morning with a positive spin as to how they compared with Acumen. The trading activity was wild. You do remember that on two prior occasions PMN surged way higher and then lost momentum. I assume the same group jumped on this once again and sold the stock short. If any insiders sold the stock short they would be in big trouble. Many of these insiders have mandatory reporting requirements for any sales or purchases. They were also aware that financing was right around the corner and that there was a blackout on selling. There is also a 60 wash sale rule that applies to selling a stock and buying back the same stock within 60 days. Why would officers, directors or billionaire shareholders risk everything to do such a risky thing. The other thing to consider is that earnings were announced a couple weeks later which also prevented any insider trading. The earnings/balance sheet showed clearly that financing was needed and quickly. You guys are crazy and you are manufacturing a conspiracy theory that is not substantiated by any facts. 
<< Previous
Bullboard Posts
Next >>